US 7,598,245 B2
Aminotriazole compounds useful as inhibitors of protein kinases
Michael J. Arnost, North Andover, Mass. (US); Guy W. Bemis, Arlington, Mass. (US); Robert J. Davies, Arlington, Mass. (US); Cornelia J. Forster, Pelham, N.H. (US); Ronald Grey, Jr., Attleboro, Mass. (US); Mark W. Ledeboer, Acton, Mass. (US); Brian Ledford, Attleboro, Mass. (US); Craig Marhefka, Rockville, Md. (US); David Messersmith, Somerville, Mass. (US); Albert C. Pierce, Cambridge, Mass. (US); Francesco G. Salituro, Marlboro, Mass. (US); and Jian Wang, Newton, Mass. (US)
Assigned to Vertex Pharmaceuticals Incorporated, Cambridge, Mass. (US)
Filed on Apr. 13, 2007, as Appl. No. 11/787,165.
Application 11/787165 is a division of application No. 10/914051, filed on Aug. 06, 2004, granted, now 7,226,920.
Claims priority of provisional application 60/492787, filed on Aug. 06, 2003.
Prior Publication US 2008/0096901 A1, Apr. 24, 2008
Int. Cl. A61K 31/427 (2006.01); A61K 31/5377 (2006.01); C07D 413/12 (2006.01); C07D 263/32 (2006.01); C07D 249/08 (2006.01)
U.S. Cl. 514—236.2  [514/365; 514/378; 514/383; 544/132; 546/2; 548/202; 548/235; 548/264.8] 22 Claims
 
1. A compound having the formula:

OG Complex Work Unit Drawing
or a pharmaceutically acceptable salt thereof, wherein
R1 is hydrogen or C1-6 alkyl;
R2 is Ar1 or Cy1, wherein Ar1 is a group selected from phenyl, pyridyl, pyrimidinyl, pyrazinyl, furanyl, thienyl pyrrolyl, pyrazolyl, triazolyl, imidazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, or thiadiazolyl and Cy1 is selected from cyclopropyl, cyclopentyl, cyclohexyl, piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, pyrazolinyl, tetrahydropyranyl, or tetrahydrofuranyl; wherein each of Ar1 and Cy1 is optionally substituted with 0-5 independent occurrences of Q—RX; wherein each independent occurrence of Q is a bond or is a C1-6 alkylidene chain wherein up to two non-adjacent methylene units of Q are optionally replaced by CO, CO2, COCO, CONR, OCONR, NRNR, NRNRCO, NRCO, NRCO2, NRCONR, SO, SO2, NRSO2, SO2NR, NRSO2NR, O, S, or NR; and each independent occurrence of RX is independently selected from R′, halogen, NO2, CN, OR′, SR′, N(R′)2, NR′C(O)R′, NR′C(O)N(R′)2, NR′CO2R′, C(O)R′, CO2R′, OC(O)R′, C(O)N(R′)2, OC(O)N(R′)2, SOR′, SO2R′, SO2N(R′)2, NR′SO2R′, NR′SO2N(R′)2, C(O)C(O)R′, or C(O)CH2C(O)R′;
wherein R3 is Ar2, wherein Ar2 is an optionally substituted aryl group selected from pyridinyl or pyrimidinyl, optionally substituted with up to five substituents selected from Z-RY; wherein Z is a bond or is a C1-6 alkylidene chain wherein up to two non-adjacent methylene units of Z are optionally replaced by CO, CO2, COCO, CONR, OCONR, NRNR, NRNRCO, NRCO, NRCO2, NRCONR, SO, SO2, NRSO2, SO2NR, NRSO2NR, O, S, or NR; and each occurrence of RY is independently selected from R′, halogen, NO2, CN, OR′, SR′, N(R′)2, NR′C(O)R′, NR′C(O)N(R′)2, NR′CO2R′, C(O)R′, CO2R′, OC(O)R′, C(O)N(R′)2, OC(O)N(R′)2, SOR′, SO2R′, SO2N(R′)2, NR′SO2R′, NR′SO2N(R′)2, C(O)C(O)R′, or C(O)CH2C(O)R′;
each occurrence of R is independently selected from hydrogen or an optionally substituted C1-6 aliphatic group; and each occurrence of R′ is independently selected from hydrogen or an optionally substituted group selected from C1-8 aliphatic, C6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 3-10 ring atoms, or wherein R and R′ taken together, or two occurrences of R′ taken together, form a 5-8 membered cycloalkyl, heterocyclyl, aryl, or heteroaryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
each of the optional substituents of said aryl or heteroaryl ring is selected from halogen; —Ro; —ORo; —SRo; 1,2-methylenedioxy; 1,2-ethylenedioxy; phenyl (Ph) optionally substituted with Ro; —O(Ph) optionally substituted with Ro; —(CH2)1-2(Ph) optionally substituted with Ro; —CH═CH(Ph) optionally substituted with Ro; —NO2; —CN; —N(Ro)2; —NRoC(O)Ro; —NRoC(S)Ro; —NRoC(O)N(Ro)2; —NRoC(S)N(Ro)2; —NRoCO2Ro; —NRoNRoC(O)Ro; —NRoNRoC(O)N(Ro)2; —NRoNRoCO2Ro; —C(O)C(O)Ro; —C(O)CH2C(O)Ro; —CO2Ro; —C(O)Ro; —C(S)Ro; —C(O)N(Ro)2; —C(S)N(Ro)2; —C═(NH)—N(Ro)2, —OC(O)N(Ro)2; —OC(O)Ro; —C(O)N(ORo)Ro; —C(NORo)Ro; —S(O)2Ro; —S(O)3Ro; —SO2N(Ro)2; —S(O)Ro; —NRoSO2N(Ro)2; —NRoSO2Ro; —N(ORo)Ro; —C(═NH)—N(Ro)2; or —(CH2)0-2NHC(O)Ro; wherein each independent occurrence of Ro is selected from hydrogen, an optionally substituted C1-6 aliphatic, an unsubstituted 5-6 membered heteroaryl or heterocyclic ring, phenyl, —O(phenyl), or —CH2(phenyl), wherein optional substituents on the aliphatic group of Ro are selected from NH2, NH(C1-4aliphatic), N(C1-4aliphatic)2, halogen, C1-4aliphatic, OH, O(C1-4aliphatic), NO2, CN, CO2H, CO2(C1-4aliphatic), O(haloC1-4aliphatic), or haloC1-4aliphatic, or two independent occurrences of Ro, on the same substituent or different substituents, taken together with the atom(s) to which each Ro group is bound, form a 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
each of the optional substituents on the nitrogen of a non-aromatic heterocyclic ring are selected from —R+, —N(R+)2, —C(O)R+, —CO2R+, —C(O)C(O)R+, —C(O)CH2C(O)R+, —SO2R+, —SO2N(R+)2, —C(═S)N(R+)2, —C(═NH)—N(R+)2, or —NR+SO2R+; wherein R+ is hydrogen, an optionally substituted C1-6 aliphatic, optionally substituted phenyl, optionally substituted —O(Ph), optionally substituted —CH2(Ph), optionally substituted —(CH2)1-2(Ph); optionally substituted —CH═CH(Ph); or an unsubstituted 5-6 membered heteroaryl or heterocyclic ring having one to four heteroatoms independently selected from oxygen, nitrogen, or sulfur, or two independent occurrences of R+, on the same substituent or different substituents, taken together with the atom(s) to which each R+ group is bound, form a 5-8-membered heterocyclyl, aryl, or heteroaryl ring or a 3-8-membered cycloalkyl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein optional substituents on the aliphatic group or the phenyl ring of R+ are selected from NH2, NH(C1-4 aliphatic), N(C1-4 aliphatic)2, halogen, C1-4 aliphatic, OH, O(C1-4 aliphatic), NO2, CN, CO2H, CO2(C1-4 aliphatic), O(halo C1-4 aliphatic), or halo(C1-4 aliphatic), wherein each of the foregoing C1-4 aliphatic groups of R+ is unsubstituted;
each of the optional substituents on said alkylidene chain, aliphatic, cycloalkyl, or heterocyclyl is selected from the list of optional substituents of optional substituents for aryl and heteroaryl rings and further comprise ═O, ═S, ═NNHR*, ═NN(R*)2, ═NNHC(O)R*, ═NNHCO2(alkyl), ═NNHSO2(alkyl), or ═NR*, where each R* is independently selected from hydrogen or a C1-6 aliphatic group; and
provided that when R3 is 4,6-dimethoxy 2-pyrimidinyl, and R1 is hydrogen, then R2 is not o-S(O)Me phenyl.